Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
OBJECTIVE: The aim of the study was to assess the clinical response to eslicarbazepine acetate (ESL) as add-on therapy in adult patients with partial-onset epilepsy by means of the time-to-baseline seizure count method.
METHODS: We retrospectively identified consecutive patients with partial-onset seizures, with or without secondary generalization, prescribed to ESL add-on therapy. The primary endpoint was the time-to-baseline monthly seizure count. Subgroup analysis was performed according to carbamazepine (CBZ)/oxcarbazepine (OXC) status (prior vs never use). Secondary outcomes were the rate of treatment-related adverse events (AEs) and the AEs affecting ≥5% of patients.
RESULTS: One-hundred and eighteen patients were included. The median time-to-baseline monthly seizure count was 46 (35-101) days in the overall study cohort. The number of concomitant anti-epileptic drugs (AEDs) was associated with the time-to-endpoint (adjusted hazard ratio [adj HR]=2.22, 95% CI 1.18-4.14, P=.013 for two AEDs vs one; adj HR=3.65, 95% CI 1.66-8.06, P=.001 for three or more AEDs vs one). Groupwise, the median times-to-baseline seizure count were 47 (35-97) and 43 (34-103) in patients with prior and never exposure to CBZ/OXC, respectively (P for log-rank test=.807). Adverse events occurred in 53.4% (63 of 118) of patients; the most frequently reported were dizziness (13.6%), somnolence (11.9%), nausea (6.8%), and fatigue (5.1%).
CONCLUSIONS: Add-on ESL improved seizure control and was overall well-tolerated in adult patients with partial-onset epilepsy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
|---|---|
| Enthalten in: |
Acta neurologica Scandinavica - 137(2018), 1 vom: 09. Jan., Seite 29-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lattanzi, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33CM23913M |
|---|
| Anmerkungen: |
Date Completed 08.06.2018 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ane.12803 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274164337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274164337 | ||
| 003 | DE-627 | ||
| 005 | 20231225002853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ane.12803 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0913.xml |
| 035 | |a (DE-627)NLM274164337 | ||
| 035 | |a (NLM)28741673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lattanzi, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2018 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: The aim of the study was to assess the clinical response to eslicarbazepine acetate (ESL) as add-on therapy in adult patients with partial-onset epilepsy by means of the time-to-baseline seizure count method | ||
| 520 | |a METHODS: We retrospectively identified consecutive patients with partial-onset seizures, with or without secondary generalization, prescribed to ESL add-on therapy. The primary endpoint was the time-to-baseline monthly seizure count. Subgroup analysis was performed according to carbamazepine (CBZ)/oxcarbazepine (OXC) status (prior vs never use). Secondary outcomes were the rate of treatment-related adverse events (AEs) and the AEs affecting ≥5% of patients | ||
| 520 | |a RESULTS: One-hundred and eighteen patients were included. The median time-to-baseline monthly seizure count was 46 (35-101) days in the overall study cohort. The number of concomitant anti-epileptic drugs (AEDs) was associated with the time-to-endpoint (adjusted hazard ratio [adj HR]=2.22, 95% CI 1.18-4.14, P=.013 for two AEDs vs one; adj HR=3.65, 95% CI 1.66-8.06, P=.001 for three or more AEDs vs one). Groupwise, the median times-to-baseline seizure count were 47 (35-97) and 43 (34-103) in patients with prior and never exposure to CBZ/OXC, respectively (P for log-rank test=.807). Adverse events occurred in 53.4% (63 of 118) of patients; the most frequently reported were dizziness (13.6%), somnolence (11.9%), nausea (6.8%), and fatigue (5.1%) | ||
| 520 | |a CONCLUSIONS: Add-on ESL improved seizure control and was overall well-tolerated in adult patients with partial-onset epilepsy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-epileptic drugs | |
| 650 | 4 | |a epilepsy | |
| 650 | 4 | |a eslicarbazepine acetate | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Dibenzazepines |2 NLM | |
| 650 | 7 | |a Carbamazepine |2 NLM | |
| 650 | 7 | |a 33CM23913M |2 NLM | |
| 650 | 7 | |a eslicarbazepine acetate |2 NLM | |
| 650 | 7 | |a BEA68ZVB2K |2 NLM | |
| 650 | 7 | |a Oxcarbazepine |2 NLM | |
| 650 | 7 | |a VZI5B1W380 |2 NLM | |
| 700 | 1 | |a Cagnetti, C |e verfasserin |4 aut | |
| 700 | 1 | |a Foschi, N |e verfasserin |4 aut | |
| 700 | 1 | |a Lorusso, A |e verfasserin |4 aut | |
| 700 | 1 | |a Provinciali, L |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestrini, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta neurologica Scandinavica |d 1961 |g 137(2018), 1 vom: 09. Jan., Seite 29-32 |w (DE-627)NLM000056022 |x 1600-0404 |7 nnns |
| 773 | 1 | 8 | |g volume:137 |g year:2018 |g number:1 |g day:09 |g month:01 |g pages:29-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ane.12803 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 137 |j 2018 |e 1 |b 09 |c 01 |h 29-32 | ||